ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

8,887 trials analyzed so far

Trials that use: Wald / z-test

2,196 results

SWITCH PROIndependent statistical analysis of A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study:…Phase 4Results postedn = 498NCT03687827
Symplicity AFIndependent statistical analysis of Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 102NCT02064764
Symptoms-StepsIndependent statistical analysis of In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 40NCT03859765
T-jet®Independent statistical analysis of Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 52NCT00990340
T1GERIndependent statistical analysis of A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 84NCT02846545
T2D_MTUIndependent statistical analysis of Impact of Muscle and Tendon Dysfunction in People With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 46NCT05585502
TALCIndependent statistical analysis of Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC):…Phase 3Results postedn = 210NCT00565266
TANGOIndependent statistical analysis of A Phase 3 Study of Tanezumab for Chronic Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 1,832NCT02528253
TAPIndependent statistical analysis of Postoperative Pain Control for Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00913068).Phase NAResults postedn = 110NCT00913068
TECH-EIndependent statistical analysis of Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 73NCT05376358
THORIndependent statistical analysis of A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations: primary endpoint…Phase 3Results postedn = 629NCT03390504
TIPIndependent statistical analysis of Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05113277).Phase NAResults postedn = 51NCT05113277
TitAINIndependent statistical analysis of A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 52NCT03765788
TITREIndependent statistical analysis of Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00710866).Phase 3Results postedn = 262NCT00710866
TOPAZIndependent statistical analysis of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 320NCT02754661
TOPAZ-1Independent statistical analysis of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 810NCT03875235
TOPSIndependent statistical analysis of Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity): primary endpoint results, effect…Phase 3Results postedn = 476NCT00124748
TRANSITIndependent statistical analysis of A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate: primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 490NCT01059773
TRILUMINATE PivotalIndependent statistical analysis of the TRILUMINATE Pivotal trial of the TriClip device in tricuspid regurgitation, including its hierarchical composite endpoint, win-ratio analysis, KCCQ, functional outcomes, safety, and statistical methodology.Phase NAResults postedn = 572NCT03904147
trinkfitIndependent statistical analysis of Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 2,950NCT00554294
TRITON3Independent statistical analysis of A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 405NCT02975934
TruEyeTotal1Independent statistical analysis of DAILIES TOTAL1 Versus ACUVUE TruEye - Effects on the Biology of the Ocular Surface and Lid Margin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 118NCT02347631
TWO2DFUIndependent statistical analysis of Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 73NCT02326337
Tysabri JapanIndependent statistical analysis of Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 106NCT01440101
UNCOVER-3Independent statistical analysis of A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01646177).Phase 3Results postedn = 1,346NCT01646177
UNIFIIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis: primary endpoint results, effect estimate…Phase 3Results postedn = 961NCT02407236
URIDxEDIndependent statistical analysis of Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02957136).Phase NAResults postedn = 194NCT02957136
V-EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 305NCT04545489
VA CARDSIndependent statistical analysis of Coronary Artery Revascularization in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326196).Phase 4Results postedn = 198NCT00326196
VEGAIndependent statistical analysis of Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396316).Phase 3Results postedn = 54NCT02396316
VERITASIndependent statistical analysis of A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal…Phase 3Results postedn = 111NCT00242580
VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.Phase 3Results postedn = 1,240NCT00637377
VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…Phase 3Results postedn = 1,217NCT00509795
VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 438NCT03562156
VisipaqueIndependent statistical analysis of Comparison of Contrast Agents During CT Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534975).Phase NAResults postedn = 513NCT01534975
Vita-ShockIndependent statistical analysis of Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786498).Phase 2Results postedn = 102NCT02786498
VITALITY-HFpEFIndependent statistical analysis of Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03547583).Phase 2Results postedn = 789NCT03547583
VitalpsIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 23NCT02104505
VR-THEIAIndependent statistical analysis of Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 180NCT03662607
VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 92NCT02038842
VRPE ExtensionIndependent statistical analysis of Comparing Virtual Reality Exposure Therapy to Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459705).Phase NAResults postedn = 162NCT01459705
WalkITIndependent statistical analysis of A Walking Intervention Through Text Messaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02053259).Phase NAResults postedn = 96NCT02053259
WHISPERIndependent statistical analysis of Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 229NCT02314000
YeapleIndependent statistical analysis of Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01040169).Phase NAResults postedn = 79NCT01040169
ZEAL UNLOCKIndependent statistical analysis of A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 73NCT06269484
ZoMARSIndependent statistical analysis of Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 48NCT01348269